➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Baxter
Colorcon
Moodys
McKinsey

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Patent: 9,458,466

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,458,466
Title:Translational control system using RNA-protein interaction motif
Abstract: A translational control method using an RNA-protein interaction motif is provided. The method comprises a step of introducing an mRNA having: a 5\'UTR regulation structure comprising: (1) a cap structure at the 5\' terminus, (2) a spacer positioned on the 3\' side of the cap structure, and (3) one or more RNA motifs positioned on the 3\' side of the spacer, which comprises an RNA-protein interaction motif-derived nucleotide sequence or a variant thereof; and a nucleotide sequence encoding a target protein gene on the 3\' side of the 5\'UTR regulation structure, into a cell in the presence of a protein specifically binding to the RNA motifs, wherein a translational level is decreased as the number of bases of the spacer decreases, and the translational level is decreased as the number of the RNA motifs increases.
Inventor(s): Saito; Hirohide (Kyoto, JP), Endo; Kei (Kyoto, JP), Inoue; Tan (Kyoto, JP)
Assignee: Kyoto University (Kyoto, JP)
Application Number:14/415,009
Patent Claims:see list of patent claims

Details for Patent 9,458,466

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Kyoto University (Kyoto, JP) 2032-07-16 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Kyoto University (Kyoto, JP) 2032-07-16 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Kyoto University (Kyoto, JP) 2032-07-16 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
AstraZeneca
McKesson
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.